<DOC>
	<DOCNO>NCT00725478</DOCNO>
	<brief_summary>The aim non-interventional Post Marketing Study investigate use non-ergot dopamine agonist piribedil ( trade name : CLARIUM ) mono- combination therapy patient Morbus Parkinson . Tolerability course disease change parkinsonian symptom stabilisation , change dopamine agonist document routine condition . Piribedil prescribe accord marketing authorisation responsible neurologist .</brief_summary>
	<brief_title>SEDPARK1 : Safety Efficacy Study With Non-ergot Dopamine-agonist Piribedil Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Piribedil</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>Male female patient 18 year old . Indication : Morbus Parkinson . Treatment piribedil first time . Monotherapy piribedil . Combination therapy LDopa ( begin secondary ) and/or combination antiparkinsonian drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Piribedil ( trade name : CLARIUM )</keyword>
	<keyword>non-ergot dopamine agonist</keyword>
	<keyword>Morbus Parkinson</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Post Marketing Surveillance</keyword>
</DOC>